[Testosterone metabolism in the skin of women with hirsutism]. 1985

L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko

A study was made of the endogenous testosterone (T) level in the blood plasma, the rate of T decomposition and the level of 5 alpha-dehydrotestosterone in the pubic skin of women with hirsutism of different genesis. As to T amounts the investigated form of androgenization can be placed in the following sequence: diencephalic form of ovarian polycystosis greater than congenital adrenogenital syndrome greater than ovarian form of polycystosis (before operation) greater than idiopathic form of hirsutism greater than ovarian form of polycystosis (after operation) greater than healthy women. The rate of T transformation into 5 alpha-dehydrotesosterone was higher but in patients with the idiopathic form of hirsutism whereas the level of 5 alpha-dehydrotestosterone was significantly decreased in all the patients. The highest amount of the metabolite was found in the patients with idiopathic hirsutism, the lowest in the diencephalic form of polycystosis and congenital adrenogenital syndrome. In all the investigated clinical forms of androgenization there is a reduced period of the presence of 5 alpha-dehydrotestosterone in the skin cells. An enhanced process of 5 alpha-dehydrotestosterone transformation into androstenediols is likely to be the most probable cause of this phenomenon. An assumption has been made as to a stimulating effect of androstenediols on the virile pattern hair growth in women.

UI MeSH Term Description Entries
D011085 Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading. Stein-Leventhal Syndrome,Polycystic Ovarian Syndrome,Polycystic Ovary Syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary Syndrome,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,Sclerocystic Ovary,Stein Leventhal Syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal
D005260 Female Females
D006628 Hirsutism A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000312 Adrenal Hyperplasia, Congenital A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders. Congenital Adrenal Hyperplasia,Hyperplasia, Congenital Adrenal,Adrenal Hyperplasias, Congenital,Congenital Adrenal Hyperplasias,Hyperplasias, Congenital Adrenal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D013196 Dihydrotestosterone A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. 5 alpha-Dihydrotestosterone,Androstanolone,Stanolone,17 beta-Hydroxy-5 beta-Androstan-3-One,17beta-Hydroxy-5alpha-Androstan-3-One,5 beta-Dihydrotestosterone,5-alpha Dihydrotestosterone,5-alpha-DHT,Anaprotin,Andractim,Dihydroepitestosterone,Gelovit,17 beta Hydroxy 5 beta Androstan 3 One,17beta Hydroxy 5alpha Androstan 3 One,5 alpha DHT,5 alpha Dihydrotestosterone,5 beta Dihydrotestosterone,Dihydrotestosterone, 5-alpha,beta-Hydroxy-5 beta-Androstan-3-One, 17
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone

Related Publications

L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
September 1965, Annals of internal medicine,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
November 1971, The Journal of laboratory and clinical medicine,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
January 1985, Problemy endokrinologii,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
January 1977, Akusherstvo i ginekologiia,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
January 1968, Revue francaise d'etudes cliniques et biologiques,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
January 1984, Acta medica Hungarica,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
December 1970, Annals of clinical research,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
January 1979, Endokrinologie,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
October 1977, The Journal of endocrinology,
L Iu Sergienko, and N G Tsarikovskaia, and L V Panchenko, and S S Popova, and T V Bondarenko
March 1966, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!